HC Deb 08 July 2003 vol 408 c774W
Bob Spink

To ask the Secretary of State for Health if he will make a statement on the availability of Glivec for leukaemia sufferers following the National Institute for Clinical Excellence provisional recommendation. [123347]

Miss Melanie Johnson

The consultation period for the National Institute for Clinical Excellence's (NICE) provisional recommendations on Glivec for the first line treatment of chronic myeloid leukaemia has closed and NICE is now in the process of preparing its final guidance. It would be inappropriate to comment in advance of the publication of NICE'S final recommendations, which are expected to be published in the autumn.